Incyte Corp. insider trading
In twelve months insiders at Incyte bought nothing and sold $57.4M on the open market; 45 of the 45 sales were under plans set months before.
New to this? How to read this page
- Insiders are the people who run the company: officers, directors and owners of 10% or more. They must report a trade on Form 4 within two business days.
- A purchase on the open market is the strongest sign: the insider spent their own money.
- A sale under a trading plan (Rule 10b5-1) says little: its dates were fixed months before. Sales outside a plan say more, but insiders sell for many reasons, such as taxes or a house.
- Grants, option exercises and shares held back for tax are left out.
- What is a Form 4? · Form 4 codes
What kind of trades
Insiders only sold: 45 sales worth $57.4M, and 45 of them were under plans set months before, which say little.
Every Form 4 line of the last twelve months, counted by kind. The grades come from the filing itself: whether the insider paid cash, whether a plan set the date, whether pay was taken in stock by choice.
Insider trades on the share price
last twelve months41 marks over twelve months, each in its grade: solid for the stronger signs, hollow or grey for the ones that say little.
The blue line is the daily close over twelve months. Each mark is one insider's trades on one day, on that day's price, sized by dollar value. Solid marks are the stronger signs; hollow and grey marks say little. Hover or tap a mark for who, how much and why.
Trades worth a closer look
A purchase stands out when two or more of these hold: a senior insider, several insiders buying within 90 days, a fall of 10% or more in the three months before, or over $1 million. A sale outside a plan is judged the same way. These are the Feed's rules.
Who traded
dollars, twelve months10 insiders traded. The most: Hoppenot Herve, sale under a plan $19.8M.
One row per insider, sold to the left and bought to the right, split by grade: the paler part of a bar is the part that says little.
How it compares
every company on the siteOpen-market sales, twelve months
Open-market purchases, twelve months
The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.
Every Form 4 line
| Traded | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 3 November 2026 | 610 | $118.96 | $72,566 | Form 4 |
| 15 October 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 15 October 2026 | 2,642 | $112.71 | $297,780 | Form 4 |
| 30 September 2026 | Clancy Paul J | Director | Took pay in stockown choice | 203 | $121.35 | $24,634 | Form 4 |
Took a $24,634 retainer as 203 shares instead of cash. The stock had risen 7% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 30 September 2026 | Harrigan Edmund | Director | Took pay in stockown choice | 206 | $121.35 | $24,998 | Form 4 |
Took a $24,998 retainer as 206 shares instead of cash. The stock had risen 7% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 15 September 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 15 September 2026 | 9,233 | $120.50 | $1.1 million | Form 4 |
| 15 September 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 15 September 2026 | 13,985 | $120.49 | $1.7 million | Form 4 |
| 19 August 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 19 August 2026 | 10,801 | $125.56 | $1.4 million | Form 4 |
| 12 August 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 12 August 2026 | 10,803 | $120.04 | $1.3 million | Form 4 |
| 5 August 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 5 August 2026 | 10,640 | $122.69 | $1.3 million | Form 4 |
| 5 August 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 5 August 2026 | 2,207 | $123.99 | $273,646 | Form 4 |
| 3 August 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 3 August 2026 | 6,055 | $120.43 | $729,204 | Form 4 |
| 31 July 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 15,888 | $119.70 | $1.9 million | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 14,661 | $119.46 | $1.8 million | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 5,332 | $119.42 | $636,747 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 2,187 | $119.47 | $261,281 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 6,171 | $119.43 | $737,003 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 4,695 | $119.39 | $560,536 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 2,864 | $119.40 | $341,962 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 1,643 | $119.51 | $196,355 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 1,642 | $119.38 | $196,022 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 85 | $122.19 | $10,386 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 326 | $121.69 | $39,671 | Form 4 |
| 31 July 2026 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 31 July 2026 | 2,293 | $119.41 | $273,807 | Form 4 |
| 16 July 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | Saletrading plan set in advance · Form 144 notice 16 July 2026 | 1,877 | $114.73 | $215,348 | Form 4 |
| 16 July 2026 | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | Saletrading plan set in advance · Form 144 notice 16 July 2026 | 1,093 | $115.01 | $125,706 | Form 4 |
| 15 July 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | Saletrading plan set in advance · Form 144 notice 16 July 2026 | 28,237 | $113.05 | $3.2 million | Form 4 |
| 30 June 2026 | Clancy Paul J | Director | Took pay in stockown choice | 252 | $113.36 | $28,567 | Form 4 |
Took a $28,567 retainer as 252 shares instead of cash. The stock had risen 20% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 30 June 2026 | Harrigan Edmund | Director | Took pay in stockown choice | 255 | $113.36 | $28,907 | Form 4 |
Took a $28,907 retainer as 255 shares instead of cash. The stock had risen 20% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 4 June 2026 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 4 June 2026 | 2,639 | $100.00 | $263,900 | Form 4 |
| 26 May 2026 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 26 May 2026 | 2,051 | $97.35 | $199,665 | Form 4 |
| 19 May 2026 | Clancy Paul J | Director | Saletrading plan set in advance · Form 144 notice 19 May 2026 | 15,000 | $94.93 | $1.4 million | Form 4 |
| 17 April 2026 | Cagnoni Pablo J | President, Global Head of R&D | Saletrading plan set in advance · Form 144 notice 17 April 2026 | 18,667 | $96.50 | $1.8 million | Form 4 |
| 31 March 2026 | Harrigan Edmund | Director | Took pay in stockown choice | 269 | $94.12 | $25,318 | Form 4 |
Took a $25,318 retainer as 269 shares instead of cash. The stock had fallen 5% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 31 March 2026 | Clancy Paul J | Director | Took pay in stockown choice | 265 | $94.12 | $24,942 | Form 4 |
Took a $24,942 retainer as 265 shares instead of cash. The stock had fallen 5% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 17 March 2026 | Cagnoni Pablo J | President, R&D | Saletrading plan set in advance · Form 144 notice 17 March 2026 | 18,667 | $94.24 | $1.8 million | Form 4 |
| 19 February 2026 | Cagnoni Pablo J | President, R&D | Saletrading plan set in advance · Form 144 notice 19 February 2026 | 18,668 | $100.91 | $1.9 million | Form 4 |
| 7 January 2026 | Issa Mohamed Khairie | EVP, Head of US Oncology | Saletrading plan set in advance · Form 144 notice 7 January 2026 | 10,856 | $109.07 | $1.2 million | Form 4 |
| 5 January 2026 | Stein Steven H | EVP & Chief Medical Officer | Saletrading plan set in advance · Form 144 notice 5 January 2026 | 15,634 | $101.70 | $1.6 million | Form 4 |
| 31 December 2025 | Clancy Paul J | Director | Took pay in stockown choice | 241 | $98.77 | $23,804 | Form 4 |
Took a $23,804 retainer as 241 shares instead of cash. The stock had risen 14% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 31 December 2025 | Harrigan Edmund | Director | Took pay in stockown choice | 245 | $98.77 | $24,199 | Form 4 |
Took a $24,199 retainer as 245 shares instead of cash. The stock had risen 14% in the three months before. The filing's own wordsRestricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1.Form 4 footnote, as filed | |||||||
| 19 December 2025 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 19 December 2025 | 2,774 | $100.00 | $277,400 | Form 4 |
| 18 December 2025 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 19 December 2025 | 600 | $98.25 | $58,950 | Form 4 |
| 17 December 2025 | Morrissey Michael James | EVP, Head of Tech. Operations | Saletrading plan set in advance · Form 144 notice 17 December 2025 | 4,323 | $97.26 | $420,455 | Form 4 |
| 16 December 2025 | Morrissey Michael James | EVP, Head of Tech. Operations | Saletrading plan set in advance · Form 144 notice 17 December 2025 | 833 | $97.42 | $81,151 | Form 4 |
| 16 December 2025 | Morrissey Michael James | EVP, Head of Tech. Operations | Saletrading plan set in advance · Form 144 notice 17 December 2025 | 53,175 | $97.29 | $5.2 million | Form 4 |
| 11 December 2025 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 11 December 2025 | 255 | $94.94 | $24,210 | Form 4 |
| 10 December 2025 | Mayes Patrick A | EVP & Chief Scientific Officer | Saletrading plan set in advance · Form 144 notice 11 December 2025 | 5,553 | $95.58 | $530,756 | Form 4 |
| 2 December 2025 | Stein Steven H | EVP & Chief Medical Officer | Saletrading plan set in advance · Form 144 notice 2 December 2025 | 20,105 | $102.51 | $2.1 million | Form 4 |
| 1 December 2025 | Stein Steven H | EVP & Chief Medical Officer | Saletrading plan set in advance · Form 144 notice 2 December 2025 | 2,559 | $102.96 | $263,475 | Form 4 |
| 24 November 2025 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 24 November 2025 | 600 | $103.00 | $61,800 | Form 4 |
| 21 November 2025 | Tray Thomas | Principal Accounting Officer | Saletrading plan set in advance · Form 144 notice 21 November 2025 | 169 | $102.00 | $17,238 | Form 4 |
| 17 November 2025 | Denton Sheila A. | EVP & General Counsel | Saletrading plan set in advance · Form 144 notice 17 November 2025 | 278 | $104.36 | $29,012 | Form 4 |
| 10 November 2025 | Hoppenot Herve | Director | Saletrading plan set in advance · Form 144 notice 10 November 2025 | 187,500 | $105.46 | $19.8 million | Form 4 |